证券代码：300636 证券简称：同和药业 公告编号：2024-062 江西同和药业股份有限公司 关于公司通过药品 GMP 符合性检查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司")于近日收到江 西省药品监督管理局的"江西省药品监督管理局药品 GMP 符合性检查 结果告知书(2024 年第 57 号)"，获悉经现场检查和综合评定,公司本 次检查原料药克立硼罗符合药品 GMP，具体信息如下： | 企业名称 | 江西同和药业股份有限公司 | | --- | --- | | 生产地址 | 江西奉新高新技术产业园区天工大道888号 | | 检查范围 | 原料药（克立硼罗） | | 检查日期 | 2024年9月11-13日 | | 检查结论 | 本次检查原料药（克立硼罗）符合药品GMP | 克立硼罗适用于2岁及以上轻度至中度特应性皮炎患者的局部外 用治疗。 公司原料药克立硼罗通过药品GMP符合性检查，有利于公司拓展 产品在国内市场的销售，形成国内国外市场同步销售的良好格局。 受市场环境等因素影响，上述原料药品种的具体销 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 12 yuan, compared to the current price of 8.66 yuan [5] Core Views - The company's Q3 2024 performance met expectations, with revenue of 570 million yuan (+1.84% YoY) and net profit attributable to shareholders of 95.74 million yuan (+21.72% YoY) [1] - Non-contract custom business grew by 13.8% YoY in the first three quarters of 2024, while contract custom business declined by 44.7% due to early termination by some clients [2] - Overseas sales contributed significantly, with export revenue reaching 460 million yuan (+6.63% YoY), while domestic sales declined by 15% to 107 million yuan [2] - New production capacity is expected to support the company's growth, particularly for new API products such as Ticagrelor, Vildagliptin, and Apixaban [3] Financial Performance - Revenue for 2024 is projected to be 795 million yuan (+10.1% YoY), with net profit attributable to shareholders of 135 million yuan (+27.3% YoY) [4] - The company's revenue is expected to grow to 1.15 billion yuan by 2026, with a net profit of 226 million yuan [4] - The company's PE ratio for 2024-2026 is estimated at 27x, 21x, and 16x, respectively [3] Business Outlook - The company is entering a new growth cycle driven by new products, with overseas API business expected to grow steadily as patents expire [2] - Domestic sales are expected to benefit from an increasing pipeline of registered products [2] - The company's new production facilities are expected to support the expansion of its API product portfolio [3] Valuation - The report suggests a 2025 PE multiple of 30x, implying a target price of 12 yuan [3] - The company's current valuation is considered reasonable given its growth prospects [3]

证券代码：300636 证券简称：同和药业 公告编号：2024-061 江西同和药业股份有限公司 关于取得发明专利证书的公告 克立硼罗临床用于3个月及以上婴幼儿以及成人的中重度湿疹的 治疗，疗效和安全性俱佳。 本发明提供一种新的克立硼罗的制备方法。与现有技术相比， 具有反应条件温和、收率高、产品质量好、生产成本低的优势，特 别适合于工业化大生产。 上述发明专利的取得不会对公司近期生产经营产生重大影响， 但有利于发挥公司自主知识产权技术优势，完善知识产权保护体 系，从而增强公司核心竞争力。 专利号：ZL 2020 1 1525126.2 专利类型：发明专利 专利申请日：2020.12.22 授权公告日：2024.10.29 专利权人：江西同和药业股份有限公司 注：专利权自授权公告之日起生效。专利权期限为二十年，自申请日起 算。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到 中华人民共和国国家知识产权局颁发的发明专利证书，具体情况如 下： 发明名称：一种克立硼罗中间体、制备方法及其在制备克立硼 罗中的应用 ...

股 票 研 究 证 券 研 究 报 告 股票研究 /[Table_Date] 2024.10.29 [table_Authors]丁丹(分析师) 0755-23976735 dingdan@gtjas.com 登记编号S0880514030001 ——同和药业 2024 年三季报点评 | --- | --- | --- | --- | --- | --- | |-----------------------|-------|-------|-------|-------|-------| | | | | | | | | 吴晗 ( 分析师 ) | | | | | | | 010-83939773 | | | | | | | wuhan024878@gtjas.com | | | | | | | S0880523080005 | | | | | | 本报告导读： 盈利能力改善，存量产品去库接近尾声，新品放量可期，看好长期成长空间。 投资要点： [Table_Summary] 维持"增持"评级。公司发布三季报业绩报告，2024Q1-Q3 营收 5.70 亿元，同比增长 1.84%，归母净利润 0.96 亿元，同比增 ...

首先我为大家做一个简要的解读然后交流的问题呢庞总也会给大家来回答分几块内容第一块我们就是先讲一下报告期的经营情况概述报告期内公司呢实现销售收入519,993.34万元同比增长1.84%其中国外销售416,334.47万元 同比增长2881.65万元增幅为6.63%国内销售10658.87万元同比下降14.82%新产品实现销售收入217396.82万元同比增长是9.89%CGMO这个板块业务实现销售收入6349.65万元同比是减少了44.66% 具体的分析下面还会展开来说一下包括其内公司实现净利润9573.65万元同比增长21.72%那么扣费的净利润是9306.13万元同比增长是29.91%毛利率为33.66%同比提升了2.37个百分点 净利率为16.8%同比提升了2.74个百分点研发投入是3920.45万元同比减少了17.12%占刚青年收入的6.88%继续保持了较高的投入水平那么这几项费用报告期内销售费用同比增长是6.34%管理费用同比下降3.93%财务费用同比下降 222.19%研发费用同比下降了17.12%销售费用增长的主要原因是因为报告期注册的认证费增加所致管理费用下降的主要原因是报告期股权基地成本减少 ...

同和药业（300636.SZ） 化学制药 证券研究报告/公司点评报告 2024 年 10 月 26 日 执业证书编号：S0740519040001 Email：zhujq@zts.com.cn 基本状况 总股本(百万股)421.53 流通股本(百万股)364.42 市价(元)8.85 市值(百万元)3,730.52 流通市值(百万元)3,225.10 股价与行业-市场走势对比 收入利润稳健增长，规范市场持续放量。分季度看，2024Q3 营业收入 1.88 亿元（+5.61%， +7.00%），归母净利润 2618 万元（+21.10%，+0.75%），扣非净利润 2554 万元（+15.94%， -5.56%）。公司 Q3 收入利润环比 Q2 基本持平，与市场预期新产品放量，环比持续加速 增长有所差异。我们认为，欧美日韩规范市场的放量是存在节奏的，需要匹配专利到期 时间、客户注册报批，但同样是粘性较强，确定性较高。从今年以来，公司规范市场的 放量持续推进，稳步提升，基本符合预期。业绩的扰动来自新兴市场、国内市场以及老 产品，同时面临价格压力、支付困难等问题。另外 Q3 存在转固折旧增加、汇兑损失等 扰动，同样 ...

公 司 报 告 公 司 季 报 点 评 证 券 研 究 报 告 医药 2024 年 10 月 25 日 同和药业(300636.SZ) 利润端维持较快增长，新品种高端市场放量有望加速 推荐（维持） 事项： 股价：8.5 元 | --- | --- | |----------------------------|--------------------| | | | | 主要数据 | | | 行业 | 医药 | | 公司网址 | www.jxsy nergy.com | | 大股东 / 持股 | 庞正伟 /14.71% | | 实际控制人 | 庞正伟 , 梁忠诚 | | 总股本 ( 百万股 ) | 422 | | 流通 A 股 ( 百万股 ) | 364 | | 流通 B/H 股 ( 百万股 ) | | | 总市值（亿元） | 36 | | 流通 A 股市值 ( 亿元 ) | 31 | | 每股净资产 ( 元 ) | 5.48 | | 资产负债率 (%) | 29.9 | 行情走势图 同和药业 = 沪深300指数 相关研究报告 【平安证券】同和药业（300636.SZ）*首次覆盖报告* 传统品种业务稳健，高端市 ...

江西同和药业股份有限公司投资者关系活动记录表 证券简称:同和药业 证券代码:300636 编号:2024011 | --- | --- | --- | --- | |------------------------|------------------------------------------------|--------------------------------------------|------------------------| | 投资者关系活动类型 | 特定对象调研 \n□媒体采访 □新闻发布会 □现场参观 | □分析师会议 \n□业绩说明会 □路演活动 □其他( | ) | | | 东吴医药 | 朱国广 俞昊岚 | 徐梓煜 | | | 中信证券 平安医药 | 陈竹 韩世通 叶寅 韩盟盟 | 王凯旋 张恒楠 臧文清 | | | | | | | | 招商证券 华安医药 | 许菲菲 梁广楷 谭国超 杨馥瑗 | 侯彪 | | | | | | | | 华创医药 | 郑辰 王宏雨 | | | | 太平洋医药 | 周豫 乔露阳 | | | | 申万医药 | 张静含 余玉君 | 仰佳佳 | | | ...

2024 年 10 月 24 日 公司点评 买入/维持 同和药业(300636) 目标价: 10.50 昨收盘:8.82 Q3 营收稳定增长，利润略低于市场预期 走势比较 (50%) (34%) (18%) (2%) 14% 30% 23/10/2324/1/424/3/1724/5/2924/8/1024/10/22 同和药业 沪深300 股票数据 总股本/流通(亿股) 4.22/3.64 总市值/流通(亿元) 37.18/32.14 12 个月内最高/最低价 (元) 12.05/5.76 相关研究报告 <>-- 2024-08-29 <<同和药业（300636）2023 年年报及 2024 年一季报点评：Q1 业绩超市场 预期，新产品法规市场即将放量>>-- 2024-04-26 <<2023 年三季报点评：Q3 业绩短期 承压，期待新产品法规市场放量>>-- 2023-10-26 证券分析师：周豫 E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师：乔露阳 E-MAIL：qiaoly@tpyzq.com 分析师登记编号：S1190524080001 ...

Revenue and Profitability - Revenue for Q3 2024 increased by 5.61% year-on-year, totaling CNY 569,933,408.38[2] - Net profit attributable to shareholders rose by 21.10% to CNY 95,736,461.60, with a year-to-date increase of 21.72%[2] - Basic earnings per share increased by 19.54% to CNY 0.2280, with diluted earnings per share showing a similar increase of 18.63%[2] - Net profit for the third quarter was ¥95,736,461.60, representing a 21.76% increase from ¥78,653,167.86 in the previous year[16] - Earnings per share increased to ¥0.2280, compared to ¥0.2143 in the same quarter last year[16] Cash Flow - Cash flow from operating activities reached CNY 162,163,824.25, reflecting a significant increase of 53.38%[2] - The net cash flow from operating activities increased by 53.38% to ¥162,163,824.25 compared to ¥105,729,138.58 in the same period last year, primarily due to a decrease in cash paid for goods and services[8] - Total cash inflow from operating activities is ¥521,186,224.17, down 6.5% from ¥557,523,692.04 in the previous period[17] - Cash outflow from operating activities decreased to ¥359,022,399.92, a reduction of 20.5% from ¥451,794,553.46 in the previous period[17] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to CNY 3,221,439,738.99, representing a 2.29% increase from the previous year[2] - Total assets amounted to ¥3,295,084,846.88, up from ¥3,221,439,738.99 at the end of the previous year[14] - Total liabilities decreased to ¥985,719,380.69 from ¥994,990,614.72 year-on-year[14] - The company's equity attributable to shareholders reached ¥2,309,365,466.19, an increase from ¥2,226,449,124.27 in the previous year[14] Accounts Receivable and Inventory - The company reported a 50.19% increase in accounts receivable, totaling CNY 106,289,452.65, primarily due to unsettled payments[5] - Accounts receivable increased to ¥106,289,452.65 from ¥70,771,939.06 in the previous period[12] - Inventory rose to ¥561,229,478.14 from ¥523,416,724.31, indicating a growth in stock levels[12] Borrowings and Financial Expenses - Long-term borrowings increased by 59.40% to CNY 398,500,000.00, attributed to new long-term loans taken during the period[6] - The company reported a decrease in short-term borrowings to ¥329,428,036.67 from ¥429,312,470.41 year-on-year[15] - Financial expenses showed a significant change, with a net income of -¥13,031,592.68 compared to -¥4,044,746.02 in the previous year[15] Tax and Investment Income - Tax and additional charges rose by 91.99% year-on-year, reaching CNY 5,380,972.73, mainly due to increased property tax[7] - Investment income surged by 100% to CNY 606,704.78, driven by higher financial management returns[7] Cash and Cash Equivalents - The company's cash and cash equivalents decreased significantly from ¥512,753,422.59 at the beginning of the period to ¥132,148,876.62 at the end of the period[12] - The ending balance of cash and cash equivalents is ¥116,345,276.10, down from ¥367,231,637.75 in the previous period[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,352[9] - The largest shareholder, Mr. Pang Zhengwei, holds 15.66% of the shares, totaling 66,009,954 shares, with 49,507,465 shares under pledge[9] Research and Development - Research and development expenses were ¥39,204,527.63, down from ¥47,477,333.47 in the same period last year[15] Audit Status - The company has not undergone an audit for the third quarter report[19]